Full text is available at the source.
Abstract
GLP-1 receptor agonists may influence neurological disease through metabolic, inflammatory, and vascular pathways.
- GLP-1 receptor agonists are established therapies for type 2 diabetes and obesity with cardiovascular benefits.
- Experimental and clinical evidence suggests they may exert additional effects relevant to neurological diseases.
- Metabolic dysfunction, chronic inflammation, oxidative stress, and neurovascular injury are mechanisms linked to neurodegeneration.
- Preclinical studies indicate that GLP-1 receptor agonists may reduce neuroinflammation and oxidative stress, and support mitochondrial function.
- Clinical findings in Parkinson's disease show encouraging signals, but biomarker evidence for disease modification is limited.
- Mixed results have been observed in Alzheimer's disease clinical trials, potentially due to various factors including disease stage and treatment duration.
Simplified